Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 9/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.44 |
| ▸ | CCR5 | P51681 | 3/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6493635 | 1.00 | OPRL1 (0.60) | OPRL1KCNH2OPRM1MEN1KMT2A | |
| SCHEMBL6493639 | 1.00 | OPRL1 (0.60) | OPRL1KCNH2OPRM1MEN1KMT2A | |
| SCHEMBL6492943 | 0.86 | OPRL1 (0.70) | OPRL1KCNH2OPRM1SLC18A3GRIN2B | |
| SCHEMBL6490537 | 0.86 | OPRL1 (0.70) | OPRL1KCNH2OPRM1SLC18A3GRIN2B | |
| SCHEMBL6490539 | 0.86 | OPRL1 (0.70) | OPRL1KCNH2OPRM1SLC18A3GRIN2B | |
| SCHEMBL6491806 | 0.86 | OPRL1 (0.70) | OPRL1KCNH2OPRM1SLC18A3GRIN2B | |
| Hydrochloric Acid SCHEMBL6493144 | 0.85 | OPRL1 (0.69) | OPRL1KCNH2OPRM1SLC18A3GRIN2B | |
| Hydrochloric Acid SCHEMBL6493150 | 0.85 | OPRL1 (0.69) | OPRL1KCNH2OPRM1SLC18A3GRIN2B | |
| SCHEMBL6492403 | 0.84 | OPRL1 (0.57) | OPRL1KCNH2OPRM1KDM1AMAOA | |
| SCHEMBL6493842 | 0.79 | OPRL1 (0.67) | OPRL1KCNH2OPRM1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969724-B2 | Compounds | SMITHKLINE BEECHAM-SPA (GB) | 2005-11-29 | — | — | US | claimed |
| US-20040024218-A1 | Novel compounds | SMITHKLINE BEECHAM SPA | 2004-02-05 | — | — | US | claimed |
| US-6969724-B2 | Compounds | SMITHKLINE BEECHAM-SPA (GB) | 2005-11-29 | — | — | US | disclosed |
| US-20040024218-A1 | Novel compounds | SMITHKLINE BEECHAM SPA | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024218-A1 | Novel compounds | OXER1, CLIC1, CCR1 | OPRL1 9/4885KCNH2 706/4885OPRM1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.